A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CR / complete response

[Related PubMed/MEDLINE]
Total Number of Papers: 6114
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CR  (>> Co-occurring Abbreviation)
Long Form:   complete response
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A prospective, randomized, double-blind trial to compare body weight-adjusted and fixed doses of palonosetron for preventing postoperative nausea and vomiting in obese female patients. BMI, PONV
2020 Association of Killer Cell Immunoglobulin-like Receptor Genotypes and Haplotypes in Dry Eye Disease Patients Treated with Restasis and Systane. DED, KIR, NPR, PCR-SSP, RS
2020 Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review. CRT
2020 Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. ASCT, FL, HT, OS, PFS, PR
2020 Clinical impact of post-induction resolution of pulmonary lesions in metastatic Ewing sarcoma. EFS, OS, WLI
2020 Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India. AHL, cHL, EFS, ERA, HR, IFRT, IR, LR, LRA, OS
2020 Comparison of the effects of radiotherapy doses of 50.4Gy and 60Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society. JES, OS, RT
2020 Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields. GBM, OS, PFS, STR, TMZ, TTFields
2020 Complete resolution of urinary incontinence with treatment improved the health-related quality of life of children with functional daytime urinary incontinence: a prospective study. DUI, HRQoL
10  2020 Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. CDC, RCC
11  2020 Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patient; a case report. ---
12  2020 Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. AUA, BCG, HgRFS, NMIBC
13  2020 Cutaneous extranodal natural killer (NK) / T - cell lymphoma: A comprehensive clinical features and outcomes analysis of 71 cases. NK, OS
14  2020 Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. AML, Bcl-2, OS, R/R
15  2020 Efficacy and safety of 5mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study. 5-HT3RA, DEX, NK1RA, OLZ
16  2020 Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. IgG2
17  2020 Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese". AML, CINV, TTF
18  2020 Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report. POLE, TMB
19  2020 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients. MALT-IPI, OS, PFS
20  2020 Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. AEs, RRMM
21  2020 High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura. H. pylori, HDD, ITP
22  2020 Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma. HL, IGEV
23  2020 Impact of Platelet Counts, Surgical Methods, and Preoperative Platelet Transfusion on the Outcome of Splenectomy for Immune Thrombocytopenia. ITP, LS, OS
24  2020 Metformin plus Megestrol Acetate (MA) compared with MA alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well differentiated endometrial cancer: a randomised controlled trial. AEH, EEC, MA
25  2020 MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients. AUC, CI, HCs, ISS, miR-146b, MM, ORR
26  2020 Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. OS, PTCL
27  2020 Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. DHL, IFRT, IIC, LS, MYC-R, OS, PFS, R-CHOP
28  2020 Pediatric acute GVHD: clinical phenotype and response to upfront steroids. GVHD, HR, OR, SR, TRM, UCB, URD
29  2020 Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. BD, CI, PFS, RA-ASCT
30  2020 Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). CI, DLBCL, FL, HR, ORR, OS, PFS
31  2020 Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. BR, DLBCL, HR, IRC, OS, PFS, pola-BR, R/R
32  2020 R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. DLBCL, R-GEM-L
33  2020 Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. CI, GVHD, MN, PR, SR
34  2020 Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study. CSU, UAS7, UCT, WCA
35  2020 Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). CTCAE, DCR, EAP, irAEs, NSCLC, ORR, OS, PD, PFS, PR, RECIST, SD
36  2020 Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. AUCs, CT, DCA, HCC, NFH, PD, PR, SD, SYUCC, TACE, ZHHAJU
37  2020 Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. ALL, CLS, HUS
38  2020 Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma. HNSCC, NPV
39  2020 Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients. DLBCL, RT
40  2020 Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. HR, LRR, OR, ORR
41  2020 Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors. mRCC, OS, PFS, SBRT, TKI
42  2020 The conventional protocol vs. a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, noninferiority clinical study. AK, PDT
43  2020 Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrence. CCPT, ESCC, PBT
44  2020 [Application of endoscopic tattooing with carbon nanoparticlet in the treatment for advanced colorectal cancer]. ACRC, PD, PR, SD
45  2019 125I implantation under computed tomography guidance to treat patients with recurrent pelvic tumors: Retrospective analysis of clinical results. CT, PR
46  2019 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. DS, HL, PD, PR, SD
47  2019 A case of an elderly patient with high-grade colorectal cancer in poor general condition who showed near complete response to chemotherapy and achieved long-term survival. BSC, PS
48  2019 A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy. i.v
49  2019 A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. CB, CTCAE, EORTC, LC, MPR-OC, ORR, PR, PTV, RTOG, SBRT, SD
50  2019 A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival. HR-MDS, mCR, OS, PR
51  2019 A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. CINV, DEX, HEC, NK1RA
52  2019 A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). PR
53  2019 A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). CLL, TF, TLS
54  2019 A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. AHCT, EOT, MM, PD-1, PR, VGPR
55  2019 A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. OS, PBLs, PFS, PR, RCR, SD, SIG
56  2019 A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. AE, MBC, PR
57  2019 A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. AE, DLT, MR, PD, PR, SD, VGPR
58  2019 A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. ASCT, MM, OS, PFS, VGPR
59  2019 A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. DLT, EGFR, PR, TKI
60  2019 A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. CFS, OS, RT, SCCA, TTF
61  2019 A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer. AUC, ORR, OS, PFS
62  2019 A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). BCD, ORR, PFS, PR, PTCLs
63  2019 A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. AEs, ECOG, HN, mFUP, mOS, mPFS, PR, SD, SGC
64  2019 A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. AI, EC, GnRH agonist, meanSD
65  2019 A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor. OS, PR, SBRT, SD, UC
66  2019 A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. AL, dFLC, OS, TNT
67  2019 A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients. NDMM
68  2019 A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). CI, LTB-FL, ORR, PD, PFS, PK, PR
69  2019 A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy. BV, cHL, DLBCL, GZL, NHL
70  2019 A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas. CHOPE, ORRs, OS, PFS, PTCLs
71  2019 A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. CLL, Hgb, OR, PR, RCD, WAIHA
72  2019 A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma. CSS, MIBC, OS, PFS, TMT, UC
73  2019 Acute myeloid leukemia: How to treat the fit patient over age 75? AML, CRi
74  2019 ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. HCC, OS, PD, PR, SD, VEGF, vWF, VWF
75  2019 Adjusted Chemotherapy According to Frailty Status in Elderly Patients With Diffuse Large B-Cell Lymphoma: Experience From a Single Referral Center in Mexico City. OS
76  2019 All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. AEs, ICd, NDMM, ORR
77  2019 AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study. AMA, LMIC, ML, OS, PN
78  2019 Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. CINV
79  2019 An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres Microspheres in treating Chinese hepatocellular carcinoma patients. CSM, DEB-TACE, HCC, ORR, OS, PFS
80  2019 Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma. AFP, MWA, PR, RFA, TACE
81  2019 Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. AS
82  2019 Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma. B-NHL, CAR, CRS, ORR, PFS
83  2019 Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. anti-PD-1, HLA
84  2019 Antiviral treatment withpegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis. CHD, CI, ET, HBsAg, HCC, HDV, NR, OR, PEG, PR, qHBsAg
85  2019 Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites? CI, DLBCL, PR, RT
86  2019 Association Between Polymorphisms in the Promoter Region of microRNA-34b/c and the Chemoradiotherapy Efficacy for Locally Advanced Esophageal Squamous Cell Carcinoma in Chinese Han Population. AUC, DHPLC, ESCC, LNM, PD, PFS, PR, ROC, SD
87  2019 Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study. HCC, LRT, OS, RFS
88  2019 Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-centre experience. DLBCL, FL, MTV, OR, PET
89  2019 Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. CI, FL, ORR, OS, PFS
90  2019 Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. ASCT, HR, NDMM, PFS
91  2019 Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. CT, PVRL, RT
92  2019 Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. BI-DMFS3, CRT, FCT, GD
93  2019 Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. AEs, CI, eVOBS, MM, nCR
94  2019 Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review. ASCT, FLAM, IFE, MGRS, sFLC
95  2019 Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12). ASCT, B-HDM, JSCT, LEN, MM, OS, PFS, sCR
96  2019 BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. ---
97  2019 Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). ASCT, BV, RRHL
98  2019 Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. DEE, HCC, mRECIST, PD, PR, SD
99  2019 CalliSpheres drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. cTACE, DEB, DEB-TACE, ORR, OS, PC group, TACE, TBA
100  2019 Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. BTC, GB, GC, PFS, PRs